DOC-2/DAB2 Interacting Protein Status in High-Risk Prostate Cancer Correlates With Outcome for Patients Treated With Radiation Therapy-Reference-Cited by-同舟云学术

DOC-2/DAB2 Interacting Protein Status in High-Risk Prostate Cancer Correlates With Outcome for Patients Treated With Radiation Therapy

Published:2014-07 Issue:4 Volume:89 Page:729-735
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Jacobs Corbin,Tumati Vasu,Kapur Payal,Yan Jingsheng,Hong David,Bhuiyan Manzerul,Xie Xian-Jin,Pistenmaa David,Yu Lan,Hsieh Jer-Tsong,Saha Debabrata,Kim D. W. Nathan

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference26 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. The epidemiology of high-risk prostate cancer;Punnen;Curr Opin Urol,2013

3. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer;Mohler;J Natl Compr Canc Netw,2010

4. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer;Horwitz;J Clin Oncol,2008

5. Duration of androgen suppression in the treatment of prostate cancer;Bolla;N Engl J Med,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression;Molecular Biology Reports;2024-06-01

2. The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target;Cancer Cell International;2023-07-12

3. DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling;Cellular Signalling;2022-07

4. DAB2IP predicts treatment response and prognosis of ESCC patients and modulates its radiosensitivity through enhancing IR-induced activation of the ASK1-JNK pathway;Cancer Cell International;2022-03-05

5. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma;Journal of Clinical Oncology;2017-11-10